General Medicines: Strengthening the Foundation of Everyday Healthcare

At AMOLYT LIFESCIENCES, general medicines form the backbone of our therapeutic mission and public health responsibility. They represent the first—and often most decisive—line of defense against the everyday diseases that collectively account for the greatest burden on individuals, families, and healthcare systems. From acute respiratory and gastrointestinal infections to chronic, high-prevalence conditions such as hypertension, anemia, dyslipidemia, and community-acquired infections, general medicines are essential to preserving population health, productivity, and resilience.

With India’s 1.4 billion people and a rapidly evolving epidemiological landscape, the scale and complexity of primary care challenges are unmatched. We approach this reality with a clear mandate: to deliver high-quality, affordable, and evidence-based essential medicines at scale, while aligning India’s healthcare priorities with global standards of care. Through this dual focus, we transform India’s epidemiological challenges into globally relevant solutions—where Indian manufacturing scale and affordability reinforce international benchmarks of quality, safety, and efficacy.

Disease Burden, Causes, and Risk Drivers

India continues to bear a disproportionate share of preventable and manageable diseases. Acute respiratory infections remain among the leading causes of outpatient visits and hospitalizations, exacerbated by air pollution, seasonal viral surges, overcrowding, and climate variability. Diarrheal diseases persist as a major public health concern, driven by enteric pathogens, water and sanitation gaps, and nutritional vulnerabilities. Nutritional anemia affects more than half of women and children, undermining maternal health, childhood development, and workforce participation.

Non-communicable diseases are rising in parallel. Hypertension, often undiagnosed and inadequately treated, affects more than a quarter of adults, fueled by high salt intake, sedentary lifestyles, stress, and urbanization. Dyslipidemia and metabolic risk factors further amplify long-term cardiovascular burden. Compounding these challenges is the growing threat of antimicrobial resistance, driven by inappropriate antibiotic use, incomplete treatment courses, and uneven stewardship practices.

Globally, similar trends are evident. Non-communicable diseases now account for nearly three-quarters of all deaths worldwide, while infectious diseases continue to impose a heavy toll—particularly in low- and middle-income countries. Aging populations, lifestyle transitions, environmental pressures, and the accelerating spread of drug-resistant pathogens underscore the urgent need for robust, scalable primary care solutions.

A Comprehensive Essential Medicines Portfolio

Our general medicines portfolio is designed to address this burden across the acute–chronic continuum, supporting early intervention, effective treatment, and long-term disease control. We deliver a broad range of essential therapies across anti-infectives, gastroenterology, cardiometabolic care, and nutrition—developed to meet the highest standards of quality while remaining accessible to patients and health systems.

Our solutions include:

• Broad-spectrum and resistance-conscious anti-infectives, aligned with antimicrobial stewardship principles
• Acid-suppressive and gastrointestinal therapies supporting effective management of common digestive disorders
• Fixed-dose combinations and polypills for hypertension and cardiometabolic risk reduction, improving adherence and outcomes
• Advanced iron and micronutrient formulations addressing nutritional anemia across vulnerable populations
• Microbiome-supportive therapies that strengthen gut health and reduce recurrence of infection

Each medicine is developed with a focus on bioequivalence, safety, real-world effectiveness, and relevance to Indian disease patterns.

Our portfolio aligns with India’s National List of Essential Medicines (NLEM), Ayushman Bharat – PM-JAY, Jan Aushadhi Kendras, and the National Action Plan on Antimicrobial Resistance, while remaining consistent with global benchmarks such as the WHO Model List of Essential Medicines and international stewardship frameworks.

Vision and Strategic Priorities

Our vision is clear: to ensure that no individual is denied timely, effective treatment for common yet consequential illnesses. General medicines are not ancillary—they are the foundation upon which equitable healthcare systems are built.

To realize this vision, we are focused on:

• Expanding access to essential medicines across urban, semi-urban, and rural settings
• Strengthening quality and supply resilience, ensuring uninterrupted availability of trusted generics
• Embedding digital tools for adherence, pharmacovigilance, and rational prescribing
• Advancing antimicrobial stewardship to safeguard the effectiveness of existing therapies
• Partnering with public health systems to support large-scale disease prevention and control programs
• Demonstrated Impact and Scale

Our commitment to general medicines is reflected in measurable outcomes. Each year, we support hundreds of millions of outpatient treatments, contributing to shorter illness duration, reduced hospitalizations, and improved chronic disease control.

Our nutrition and anemia initiatives have strengthened maternal and child health outcomes, while our cardiometabolic therapies have improved blood pressure and lipid control in large patient populations.

Digital primary care platforms and telemedicine-supported diagnostics have further expanded reach—narrowing urban–rural gaps and enabling earlier, more accurate treatment decisions at the community level.

Addressing Systemic Challenges

Despite progress, challenges remain. High out-of-pocket expenditure, uneven access to diagnostics, supply-chain disruptions, counterfeit medicines, and rising antimicrobial resistance continue to threaten primary care effectiveness. Globally, essential medicine shortages and quality concerns persist, particularly in resource-constrained settings.

We address these challenges through robust quality systems, transparent supply chains, digital traceability, clinician education, and policy engagement—ensuring sustainability alongside scale.

Enduring Commitment to Everyday Health

Guided by our core values of scientific rigor, ethical governance, patient-centricity, and collaborative partnership, we continue to invest in strengthening general medicines as the foundation of healthcare delivery.

Through close collaboration with government programs, global health institutions, healthcare professionals, and technology partners, we are building resilient primary care ecosystems that can respond to today’s needs and tomorrow’s risks.

Our ambition is both practical and profound: to positively impact the everyday health of over one billion people by 2035, reduce preventable illness and disability, and position India as a global leader in essential medicines innovation and access.

Because strong healthcare systems begin with strong primary care—and general medicines are where health truly begins.